Oral Antifungal Drug Shows Promising Results in Invasive Aspergillosis Trial

The Phase 3 OASIS study has reported positive topline results for olorofim, an investigational oral antifungal drug. The study demonstrated that olorofim was non-inferior to existing treatments for invasive aspergillosis, exhibiting comparable efficacy and a favorable safety profile. This development could offer a new treatment option for patients, particularly those who cannot use azole therapies.